Biomedicine & Pharmacotherapy, Год журнала: 2025, Номер 186, С. 118011 - 118011
Опубликована: Март 31, 2025
Язык: Английский
Biomedicine & Pharmacotherapy, Год журнала: 2025, Номер 186, С. 118011 - 118011
Опубликована: Март 31, 2025
Язык: Английский
Molecular Biomedicine, Год журнала: 2025, Номер 6(1)
Опубликована: Фев. 6, 2025
Abstract Type 2 diabetes mellitus (T2DM) has rapidly increased worldwide, emerging as the fifth leading cause of death. The treatment T2DM is challenging due to side effects oral hypoglycemic drugs and limited efficacy long-term insulin therapy, which can lead resistance (IR). Consequently, there significant in discovering new that have minimal a pronounced effect. In obesity, microRNA levels been implicated glucose metabolism disorders T2DM, although many aspects remain unresolved. Here, we confirmed visceral adipose tissue serum microRNA-450a-5p content under obesity it was significantly positively associated with fasting blood glucose, triglycerides, cholesterol, low-density lipoproteins-cholesterol subjects. high-fat diet (HFD)-induced obese mice, expression serum, liver, white tissue. Moreover, Dicer -knockout mouse model constructed identify main source microRNA-450a-5p. could inactivate signal pathway by targeting inhibited Dual Specificity Phosphatase 10 (DUSP10) inducing IR vitro cultured hepatocytes adipocytes. Additionally, found regulate DUSP10 signaling activity, influencing tolerance sensitivity across various models, including normal diet, HFD-induced obese, tissue-specific microRNA-450a-5p-knockout, db/db mice. Furthermore, gallic acid might play potential role inhibiting decreasing expression. Thus, emerges an attractive therapeutic target for addressing IR, T2DM.
Язык: Английский
Процитировано
0Free Radical Biology and Medicine, Год журнала: 2025, Номер unknown
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0Biomedicine & Pharmacotherapy, Год журнала: 2025, Номер 186, С. 118011 - 118011
Опубликована: Март 31, 2025
Язык: Английский
Процитировано
0